Intracranial Nanogel Pellets Carrying Temozolomide and Paclitaxel for Adjuvant Brain Cancer Therapy

• DOI: 10.1021/acs.molpharmaceut.4c00708
• Publication Date: 2024-12-12T22:09:13Z
• Authors: Hasan Slika; Aanya Shahani; Kranthi Gattu; Varsha Mundrathi; Ameilia A. Solan; Brianna Gonzalez; Tasmima N. Haque; Sadia Rahman; Vrashabh V. Sugandhi; Jennifer Lee; Esteban Velarde; Safwan Alomari; Victor Lance Pacis; Henry Brem; Betty Tyler; Xiaoban Xin; Hyunah Cho
• Keywords: Nanogel; Temozolomide; Brain cancer; Adjuvant Therapy

Glioblastoma multiforme is the most frequently diagnosed primary malignant brain tumor. Despite multimodal therapy with surgical resection, radiation therapy, and chemotherapy, recurrence of tumor almost always guaranteed due to infiltrative nature disease. Moreover, blood barrier imparts an additional layer complexity by impeding delivery therapeutic agents tumor, hence limiting efficacy systemically delivered drugs. Hence, overcome this obstacle avoid treatment resistance, local combination therapies has risen as appealing adjuvant treatment. The present study describes creation a novel PLGA-PEG-PLGA-based nanogel pellet system for interstitial Temozolomide (TMZ) paclitaxel (PTX) brain. was shown be stable at ambient temperature, absorb water, change gel formulation physiological achieve gradual long-term release TMZ PTX in vitro. Additionally, vivo testing TMZ/PTX-loaded pellets orthotopic CT2A mouse model 9L rat acceptable safety profile when implanted intracranially significant improvement overall survival.